


# Better together, moving ahead

Randi Kudner

Assistant Director of Quality Improvement



## Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus Paper

James A. Hayman, MD, Andre Dekker, PhD, Mary Feng, MD, Sameer R. Keole, MD, Todd R. McNutt, PhD, Mitchell Machtay, MD, Neil E. Martin, MD, MPH, Charles S. Mayo, PhD, Todd Pawlicki, PhD, Benjamin D. Smith, MD, Randi Kudner, MA, Samantha Dawes, CMD, James B. Yu, MD, MHS

In 2018 ASTRO convened a group to identify a minimum set of data elements that should be required for all radiation oncology use cases.

10 data concepts were recommended including a list of techniques and modalities.

Data Element	Definition	Detail
<b>Treatment Course Data Elements</b>		
<i>Diagnosis</i>	Identify disease(s) relevant to treatment	ICD-10
<i>Modality</i>	Radiation type - Records the list of all modalities used during treatment course (Check all that apply)	Reference Table 2 for detail
<i>Technique</i>	Treatment delivery method - Records the list of all techniques used during treatment course (Check all that apply)	Reference Table 2 for detail
<i>Number of fractions planned</i>	Records the total number of treatments prescribed in a treatment	
<i>Number of fractions delivered</i>	Records the total number of treatments delivered in a treatment course	
<i>Start date of treatment</i>	Indicates the date on which the patient commences course of delivered radiation treatment	MMDDYYYY
<i>End date of treatment</i>	Indicates the date on which the patient ends/completes a course of delivered radiation treatment	MMDDYYYY
<b>Prescribed Dose Level Data Elements</b>		
(Note: Multiple dose levels are possible for a given treatment. The following elements are completed for each dose level)		
<i>Anatomic site of each prescribed dose level</i>	Indicates the primary anatomic site(s) targets for each dose level	Reference the Standards for Oncology Registry Entry (Supplemental material)
<i>Total dose planned for each prescribed dose level</i>	Dose prescribed to each dose level	cGy
<i>Total dose delivered for each prescribed dose level</i>	Dose delivered to each dose level	cGy

# ASTRO joins mCODE Executive Committee

## mCODE™ Initiative Collaborators

### Many Stakeholders Collaborate to Develop mCODE

mCODE is governed by the mCODE Executive Committee, a small, agile group of four to seven public and private entities who have voluntarily come together to further mCODE adoption.


The mCODE Executive Committee members include:

- [The Alliance for Clinical Trials in Oncology Foundation](#)
- [The American Society of Clinical Oncology \(ASCO\)](#) and its nonprofit subsidiary, [CancerLinQ LLC](#)
- [The MITRE Corporation](#)
- [The American Society for Radiation Oncology \(ASTRO\)](#)
- [The Society of Surgical Oncology](#)



**Every Patient's Journey Can  
Improve All Future Care**

# 2019 mCODE v1.0



# CodeX Oncology Use-Cases



mCODE++ Extraction



EHR Endpoints for Cancer Clinical Trials  
(including, future extensions of the ICAREdata study)



Integrated Trial Matching for  
Cancer Patients and Providers



Cancer Registry Reporting



Radiation Therapy Treatment Data for Cancer



Prior Authorization in Oncology



Risk Evaluation and Mitigation Strategies (REMS)



Quality Measures for Cancer



Structuring inclusion and exclusion trial matching criteria



Regulatory grade RWE



Oncology nurse case manager

----- *Stages* -----



Discovery



Planning



Execution



Pre-Discovery

# CodeX Oncology Use-Cases



mCODE++ Extraction



EHR Endpoints for Cancer Clinical Trials  
(including, future extensions of the ICAREdata study)



Integrated Trial Matching for  
Cancer Patients and Providers



Cancer Registry Reporting



Radiation Therapy Treatment Data for Cancer




Prior Authorization in Oncology



Risk Evaluation and Mitigation Strategies (REMS)



Quality Measures for Cancer



Structuring inclusion and exclusion trial matching criteria



Regulatory grade RWE



Oncology nurse case manager

----- *Stages* -----



Discovery



Planning



Execution



Pre-Discovery


# Radiation Therapy Treatment Data for Cancer

## Problem

- Treatment details – critical for care coordination – are not readily available in systems other than radiation oncology EHR modules: data is generally manually entered into summary documents, creating clinical burden and potential patient safety issues

## Solution

- To develop, test and deploy open data standards that enable interoperable, multi-purpose exchange of radiation treatment summary data for care coordination and data reuse.



varian



MITRE



COMP  
Canadian Organization  
of Medical Physicists



Elekta



RaySearch  
Laboratories

## Course Summary

Left Breast : 4256 cGy in 16 sessions  
 Left Left Axillary Nodes, SC and IMN: 4256 cGy in 16 sessions  
 Left Breast Surgical Bed: 5256 cGy in 20 sessions  
 Right Breast: 4256 cGy in 16 sessions  
 All treated in 20 sessions over 26 days

## Phase Summary

**Phase Name: Left Breast Tangents**  
 Target Volumes  
 • Left Breast : 4256 cGy  
 • Left Breast Surgical Bed : 4256 cGy  
 • Left Axillary Nodes, SC and IMN: 4256 cGy  
 Treated in 16 phase fractions  
 Using Photons 3D

**Phase Name: Left Breast Boost**  
 Target Volumes  
 • Left Breast Surgical Bed: 1000 cGy  
 Treated in 4 phase fractions  
 Using Electrons 3D

**Phase Name: Right Breast Tangents**  
 Target Volumes  
 • Right Breast : 4256 cGy  
 Treated in 16 phase fractions  
 Using Photons 3D

## Delivered Treatment Plan


**Breast\_L\_Tang**  
*(3 delivered of 16 planned)*

**Breast\_L\_Tang:1**  
 Adaptation  
*(13 fractions delivered of 13 planned)*

**Breast\_L\_Boost**  
*(4 fractions delivered of 4 planned)*

**Breast\_R\_Tang**  
*(16 fractions delivered of 16 planned)*

Concept	Name																				Numbering	
Course	Bilateral Breast w Boost	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	Sessions
Phase	Left Breast Tangents	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16					Phase Fractions
Treatment Plans	Breast_L_Tang <i>(3 delivered of 16 planned)</i>	1	2	3																		Plan Fractions
	Breast_L_Tang:1 <i>(Adaptation)</i>				1	2	3	4	5	6	7	8	9	10	11	12	13					Plan Fractions
Phase	Left Breast Boost																	1	2	3	4	Phase Fractions
Treatment Plan	Breast_L_Boost																	1	2	3	4	Plan Fractions
Phase	Right Breast Tangents					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	Phase Fractions
Treatment Plan	Breast_R_Tang					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	Plan Fractions



Standard FHIR Elements  
 < Extension defined in mCODE >  
 << Extension defined in CodeX RT >>

# May 2022 – IHE-RO Connect-a-thon



Manage Prescription | Manage Templates | Manage List Values

Date Range

Prescription List | New Prescription | Reload

**C1Prostate** COMPLETED

RxProstate:1 : RO

Volume	Prescriber	Plan	Planned Dose per Fraction (Gy)	Number of Fractions	Delivered	Planned	Linked Plans
Prostate	2.000						PChange1
RxProstate:1	PChange1		2.000	4/4	8.000	8.000	
Prostate	1.800	PPPrimary	1.800	3/3	5.400	5.400	PPPrimary
Sum of visible Plans					13.400	13.400	

**Approved Dose Summary (Gy)**

Delivered Dose	13.400
Remaining Planned Dose	+ 0.000
Dose Corrections	+ 0.000
<b>Dose to be Recorded (this Course)</b>	<b>= 13.400</b>
Delivered Dose	+ 0.000
Remaining Planned Dose (other Courses)	+ 0.000
<b>Total Dose to be Recorded (all Courses)</b>	<b>= 13.400</b>

**XRTS Actors, Transactions, and Content Modules**

This section defines the actors, transactions, and/or content modules in this profile. General definitions of actors are given in the Technical Frameworks General Introduction Appendix A. IHE Transactions can be found in the Technical Frameworks General Introduction Appendix B. Both appendices are located at <http://www.hl7.org/implement/standards>.

Figure X.1.1 shows the actors directly involved in the XRTS Profile and the relevant transactions between them. It also depicts possible grouping of RO Resource Repository and integration with existing IHE Central Infrastructure in case it contains a FHIR server which would then be used for storage and retrieval of RO Treatment Summary resources.

**IHE RO XRTS Validator**  
Version 2.0  
Copyright © 2020  
<https://github.com>

IHE-RO XRTS Validator is a free software for the contributing members of AAPM. You can redistribute it to other contributing members of AAPM and/or modify it under the terms of the GNU Lesser General Public License as published by the Free Software Foundation, either version 3.0 of the license, or at your option any later version if you are a contributing member of AAPM.

IHE-RO XRTS Validator is distributed in the hope that it will be useful, but WITHOUT ANY WARRANTY, without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the GNU Lesser General Public License for more details.

You should have received a copy of the GNU Lesser General Public License along with this tool; if not, see <http://www.gnu.org/licenses/>

[Epic's Radiation Therapy Summary Module – unable to share screenshots due to copyright restrictions]

RayCone

Summary | Details | Activities | Clinical profile | Care administration | Documentation | Radiation therapy | Images

Treatment history | Treatment intent | Prescriptions | Plan overview | Planning instructions | Setup instructions | Offline image review | Treatment course


**Prescriptions**

Prescription	Average dose	Summed dose	Partials type	Partials	Partials status	Partials date
Prostate	202.04 cGy (RBE) x 4 Fr = 808.16 cGy (RBE)	808.16 cGy (RBE)	Prostate	Approved	0	0
Prostate	202.04 cGy (RBE) x 4 Fr = 808.16 cGy (RBE)	808.16 cGy (RBE)	Prostate	Partially delivered	94.08	94.08
Prostate	188.16 cGy (RBE) x 4 Fr = 752.64 cGy (RBE)	752.64 cGy (RBE)	Prostate	Approved	0	0
Prostate	188.16 cGy (RBE) x 4 Fr = 752.64 cGy (RBE)	752.64 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Partially delivered	103.23	103.23
Prostate	206.47 cGy (RBE) x 4 Fr = 825.88 cGy (RBE)	825.88 cGy (RBE)	Prostate	Approved	0	0
Prostate	206.47 cGy (RBE) x 4 Fr = 82					


# mCODE STU 2

Click embedded links to see FHIR artifact definitions

This illustration is not a formal part of the mCODE specification. For brevity and clarity, names and structural relationships shown here may deviate from the specification.



# Multi-Professional Society Engagement



# Health Equity Achievement in Radiation Therapy

- HEART was developed to measure health equity issues within radiation oncology and proposed by ASTRO for inclusion in the RO Model.
- AAPM added Social Determinants of Health (SDOH) into OORO
- Collaboration on promoting addition of additional SDOH measures (e.g., disability) and identifying common standard value sets
- Exploring overlaps with mCODE and the HL7 Gravity accelerator.

HealthIT.gov  
Interoperability Standards Advisory (ISA)

Official Website of The Office of the National Coordinator for Health Information Technology (ONC)

CONTACT | EMAIL UPDATES

Connect with us: LinkedIn Twitter YouTube RSS | Log in

Home | About the ISA | ISA Content | ISA Publications | Recent ISA Updates | 21st Century Cures

Home > 21st Century Cures > USCDI

21st Century Cures

USCDI

Standards Version  
Advancement Process  
(SVAP)

United States Core Data for Interoperability (USCDI)

The United States Core Data for Interoperability (USCDI) is a standardized set of health data classes and constituent data elements for nationwide, interoperable health information exchange. Review the [USCDI Fact Sheet](#) to learn more.

For data class description and applicable

USCDI V1 | USCDI V2 | **Draft USCDI V3** | Level 2 | Level 1 | Comment

The Draft USCDI v3 contains data classes and elements from USCDI v2 and new data classes and elements submitted through the ONDEC system. Please reference the **Draft USCDI Version 3 document** to the left for applicable vocabulary standards versions associated with Draft USCDI v3 and to the **ONC Standards Bulletin 22-1** for more information about the development of Draft USCDI v3 and how you can provide feedback on it.

<p><b>Allergies and Intolerances</b></p> <p>Represents harmful or undesirable physiological response associated with exposure to a substance.</p> <p>Substance (Medication) Substance (Drug Class) <a href="#">Reaction</a></p>	<p><b>Goals</b></p> <p>An expressed desired health state to be achieved by a subject of care (or family/group).</p> <p>Patient Goals SDOH Goals</p>	<p><b>Problems</b></p> <p>Information about a condition, diagnosis, or other event, situation, issue, or clinical concept that is documented.</p> <p>Problems SDOH Problems/Health Concerns Date of Diagnosis Date of Resolution</p>
<p><b>Assessment and Plan of Treatment</b></p> <p>Represents a health</p>	<p><b>Health Insurance Information</b></p> <p>Data related to an individual's insurance coverage for health care.</p>	

# United States Core Data for Interoperability

Outgrowth of 21<sup>st</sup> Century Cures Act

National effort to identify data classes for interoperable data exchange


# CodeX Prior Authorization in Oncology

## Problem

- Prior authorization imposes a burden on patients, providers, and payers
- Prior authorization documentation requirements vary by payer plan
- Current manual processes are costly and may delay treatment

## Solution

- Reduce clinical burden when requesting oncology treatment regimens by building on Da Vinci CRD/DTR/PAS specifications to supplement prior authorization request with mCODE data elements.



## Desired Impact

- Develop automated prior authorization capability in which 80% of approvals do not require manual inspection

## Da Vinci Exchange

- Implementing this use case in oncology produces the standardized exchange for use in any specialty or other PA services or procedure.


# Quality Measure for Cancer

## Problem

- Complexity of siloed data sources, slow development process, unstandardized data

## Solution

- Create a solution that demonstrates the ability to develop FHIR digital measures using mCODE for value-based programs and clinical quality improvement in oncology.





**Randi Kudner**

Assistant Director of Quality Improvement

[Randi.Kudner@astro.org](mailto:Randi.Kudner@astro.org)